Next Article in Journal
Exploration of Factors Affecting Post-Secondary Students’ Stress and Academic Success: Application of the Socio-Ecological Model for Health Promotion
Next Article in Special Issue
A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity
Previous Article in Journal
Pregnancy Outcome during the First COVID 19 Lockdown in Vienna, Austria
Previous Article in Special Issue
Is Handedness at Five Associated with Prenatal Factors?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparison of Mean Platelet Counts in Preterm Infants with and without Retinopathy of Prematurity

1
Department of Ophthalmology and Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia
2
Hospital Universiti Sains Malaysia, Jalan Raja Perempuan Zainab 2, Kota Bharu Kelantan 16150, Malaysia
3
Department of Paediatrics, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia
*
Authors to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(7), 3783; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073783
Submission received: 18 December 2020 / Revised: 6 February 2021 / Accepted: 12 February 2021 / Published: 5 April 2021

Abstract

:
Platelets are a primary source of pro- and anti-angiogenic cytokines. However, the evidence of their role in retinopathy of prematurity (ROP) is controversial. This retrospective study aimed to compare mean weekly platelet counts between infants with and without ROP over the first 6 weeks of life. A total of 93 infants matched by gestational age and birth weight were recruited (31 with ROP, 62 without ROP). Weekly mean platelet counts and other related risk factors were documented. The repeated measure analysis of variance (ANOVA) and the repeated measure analysis of covariance (ANCOVA) were used to compare mean platelet counts over time between the two groups, with and without adjusting for confounders. We found significant differences in the weekly mean platelet counts of infants with and without ROP over the first 6 weeks of life (p = 0.002). These differences disappeared after adjusting for covariates (p = 0.489). Lower mean platelet counts in ROP infants are not directly related to ROP, but rather to the presence of other risk factors for ROP, such as culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia.

1. Introduction

Retinopathy of prematurity (ROP) is a proliferative disorder of the retinal vasculature in premature infants. It is the leading cause of preventable blindness in children globally, with reported rates of blindness ranging from 10 to 40% [1,2,3]. The pathogenesis of ROP is multifactorial, with low birth weight, low gestational age and supplemental oxygenation being some of the implicated risk factors [4,5,6,7,8]. An imbalance of pro-angiogenic and anti-angiogenic cytokines is hypothesized to be the cause of retinal neovascularization and its sequelae in ROP. Platelets, being a source of these cytokines [9,10,11], may have a role in ROP development.
To date, the relationship between platelet counts and ROP remains poorly defined. Most studies observe an association between thrombocytopenia and ROP development or severity [12,13,14], while others find no association [15,16]; one recent study even documented that thrombocytosis is associated with ROP [17]. These differences may be attributed to differences in study methodology and statistical analysis, as the majority of these studies evaluated platelet levels as a qualitative variable. Quantification of platelet levels during the first 6 weeks of life may serve as an early indicator of ROP. Thus, this study aimed to compare mean weekly platelet counts between infants with and without ROP.

2. Materials and Methods

2.1. Study Population

This was a retrospective study among preterm infants admitted to Hospital Universiti Sains Malaysia from September 2016 to December 2019. A total of 93 infants were included in this study. The study was approved by the Human Research Ethics Committee of Universiti Sains Malaysia (USM/JEPeM/18090441). The conduct of the study followed the tenets of the Declaration of Helsinki. Inclusion criteria included all premature infants with a gestational age of less than 32 weeks and a birth weight less than 1.5 kg. Infants with significant congenital abnormalities, infants with ocular defects and infants who died before their ROP status was known were excluded. Each ROP case was individually matched to two non-ROP cases (1:2), with birth weight within 100 g and gestational age within 1 week of the study subjects. Subjects with extremely small gestational age or birth weight who could not be matched were excluded. Subjects with individual or parental history of platelet-related diseases (e.g., idiopathic thrombocytopenic purpura, hemangioma and trisomy diseases) were also excluded.

2.2. Data Collection

Data collected included birth weight, gestational age, gender, ROP stage, treatment and weekly mean platelet cell count from birth to week 6 of life. ROP stages were categorized into five stages as follows: Stage 1—demarcation line, i.e., a thin line separating the avascular retina anteriorly from the vascularized retina posteriorly; Stage 2—ridge, a raised demarcation line with width and height; Stage 3—extraretinal fibrovascular proliferation, in which neovascularization extends from the ridge to the vitreous; Stage 4—partial retinal detachment, extrafoveal (Stage 4a) or foveal (Stage 4b); Stage 5—total retinal detachment, in which total retinal detachment may be exudative or tractional [18]. Associated risk factors for ROP, including necrotizing enterocolitis, intraventricular hemorrhage, culture-proven sepsis, bronchopulmonary dysplasia, duration of supplemental oxygenation and total volume of blood transfusion were also documented.

2.3. Sample Size Calculation

Sample size calculation was determined using G Power Software 2010. The calculation was based on the repeated measure ANCOVA, with an effect size of 0.25, alpha of 0.05 and power of 0.8. This provided a sample size of 74. By allowing for 20% missing data, the total sample size was 93. A 1:2 ratio was used as ROP is much less common than the absence of ROP in a normal population.

2.4. Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp, Armonk, NY, USA). A chi-square test was performed to determine the differences in categorical risk factors between infants with and without ROP. An independent t-test was used to determine the mean differences in numerical variables between the two groups. Forward stepwise multiple logistic regression was used to screen for confounding factors (i.e., other factors associated with ROP which may have influenced platelet counts). Repeated measure analysis of variance (ANOVA) was performed to determine the mean differences in weekly platelet counts from birth to week 6 of life between infants with and without ROP. The mean platelet count was then adjusted for confounding factors identified during logistic regression using the repeated measure analysis of covariance (ANCOVA). The repeated measure ANCOVA between groups was used to compare intergroup differences in mean platelet counts at specific times, and repeated measure ANCOVA within–between groups was used to compare changes in mean platelet count across time between groups. A comparison of mean platelet counts between different stages of ROP was similarly performed.

3. Results

A total of 93 infants were included in this study. The ROP group consisted of 31 infants and the group without ROP consisted of 62 infants. Of those with ROP, 8 (25.8%) had stage 1 ROP, 6 (19.3%) had stage 2 ROP, 16 (51.6%) had stage 3 ROP and only 1 (3.2%) had stage 4 ROP. The majority of these (19 infants, 61.3%) required treatment. Other clinical characteristics of our study subjects are shown in Table 1.
In univariate analysis, mean birth weight (OR 0.95, 95% CI 0.91–0.99), mean gestational age (OR 0.997, 95% CI 0.994–0.999), amount of blood transfusion (OR 1.04, 95% CI 1.02–1.05), duration of supplemental oxygenation (OR 1.16, 95% CI 1.05–1.29), culture-proven sepsis (OR 15.46, 95% CI 4.50–53.12) and bronchopulmonary dysplasia (OR 12.42, 95% CI 3.16–48.72) were statistically significant risk factors for the development of ROP. However, multivariable analysis identified only blood transfusion (OR, 1.03, 95%, CI 1.010–1.056), bronchopulmonary dysplasia (OR 6.41, 95% CI 1.28–31.93) and culture-proven sepsis (OR 8.79, 95% CI 2.09–36.93) as independent risk factors for ROP. Table 2 summarizes these results.
We found significant differences in the weekly mean platelet count between infants with and without ROP from week 2 to week 6 of life. However, repeated analysis with adjustments for covariates found no significant differences (Table 3). Overall, although there were significant intergroup differences in the change of mean platelet counts over the first 6 weeks (p = 0.002), this significance was lost after adjusting for confounders (p = 0.489). The unadjusted and adjusted mean platelet count in each group is illustrated in Figure 1. Similarly, a comparison of weekly mean platelet counts between the different stages of ROP revealed significant differences, although this significance once again disappeared after adjusting for covariates (p = 0.926 ) (Table 4).

4. Discussion

Advances in neonatal care have contributed to improved survival of preterm infants, particularly in technologically developed regions [18,19]. The incidence of ROP in high-income nations is decreasing, while in poorer regions, the converse is true [2,20]. ROP demographics and risk factors appear to vary worldwide, with severe ROP occurring even in more mature infants in low- and middle-income countries [1,21]. Identifying risk factors for ROP may enhance the efficacy of screening programs. Various studies have attempted to clarify the relationship between platelet counts and ROP [12,13,14,15,16,19,20,21,22,23] (Table 5). To our best knowledge, this is the first study to document that adjusted weekly mean platelet counts over the first 6 weeks of life have no direct relationship with ROP.
We observed that infants with ROP had significantly lower weekly unadjusted mean platelet counts from week 2 to week 6 of life, compared to their counterparts without ROP. Although this finding is consistent with the literature, limitations of previous approaches are that treating thrombocytopenia as a categorical variable (i.e., a single episode of platelet count less than 150,000/μL) may be too general of an approach and that failure to adjust for the effect of other parameters on platelets may confound the results [12,13,14]. Our study found that after adjusting for confounders, the intergroup significance between the differences in mean platelet counts disappeared. This is in keeping with the results of Korkmaz et al., who found no difference in mean platelet counts between ROP and control groups [16].
The change in mean platelet counts after adjustment may be attributed to the effect of the confounding factors (volume of blood transfusion, sepsis and presence of bronchopulmonary dysplasia) on ROP [24,25,26,27]. Sepsis is commonly known to be related to thrombocytopenia. Sepsis not only causes endothelial damage with resultant increased platelet activation, initiating a vicious cycle of subsequent platelet-mediated cytotoxic endothelium damage [28], but also causes bone marrow suppression, with consequent decreased platelet production [29]. A meta-analysis investigating the association between sepsis and ROP found that sepsis increases the risk of ROP [26]. This is consistent with our study. The hypothesized mechanisms by which sepsis results in ROP development are manifold. Firstly, sepsis could increase oxidative stress responses, leading to vascular cell degeneration and necrosis [30]. Besides that, microorganisms and toxins could cause damage to vascular endothelial cells, resulting in retinal nonperfusion [31]. We hypothesize that reduction in platelet counts indirectly reflects the ongoing septic process which predisposes these infants to ROP.
Preterm infants often have immature hematopoietic systems with inefficient erythropoiesis. The frequent phlebotomies required in these infants place them at greater risk of requiring blood transfusions [32]. Red blood cell transfusion has been shown to be an independent risk factor for the development of ROP, and this risk is proportionate to the volume transfused [25]. The increase in mean platelet counts after adjusting for blood transfusion suggests that infants with higher amounts of blood transfusions have lower platelet counts. Blood transfusions may cause platelet activation and aggregation [33,34], causing micro-occlusion of retinal vessels and resulting in platelet consumption from the bloodstream. Besides that, the shift in the ratio between adult and fetal hemoglobin, which has a higher affinity to oxygen, may cause relative hyperoxia [35], setting the stage for ROP development [36]. ROP severity has not been shown to differ between liberal and restrictive transfusion policies, so hemoglobin thresholds for transfusion should be based upon evidence-based recommendations [37,38].
In bronchopulmonary dysplasia, anomalous lung development with altered alveolar microvasculature results in inefficient gas exchange [39,40]. In fact, ventilation–perfusion abnormalities and prominent perfusion defects have been demonstrated in children up to a decade after development of this disease [41]. Animal studies show that chronic hypoxia decreases platelet counts [42,43]. Platelet deficiency may subsequently compound the disease severity, as platelet-derived growth factors are key components of normal alveolarization [44].
Platelet counts decrease within the first week of life and then increase over the next few weeks before they plateau. The increase in megakaryopoiesis is stimulated by increased thrombopoietin production during the first week of life [45]. Platelets being a primary source of vascular endothelial growth factor (VEGF) [11], we postulated that reduced platelet counts during the early phase of ROP development cause a decrease in systemic VEGF, reducing the amount of available VEGF in the eye and inhibiting normal angiogenesis. An alternate premise was that decreased platelet-derived anti-angiogenic stimuli may predispose an individual retina to neovascularization. The results of this study demonstrate that neither of these two hypotheses is likely; rather, the observed reduction in platelet levels in ROP occurs as an indirect effect of the other processes, which compounds the underlying susceptibility of these infants to ROP.
Our study’s findings may be extrapolated to similar populations, as we strictly adhered to guidelines for neonatal care, including policies for oxygen saturation monitoring, blood transfusion and ROP screening, and the mortality rate of the population of this study is comparable to that of other middle-income countries [46,47]. The strengths of this study are its use of weekly platelet counts in early life and utilization of statistical techniques which allowed adjustment for multiple confounders. There are a number of limitations in our study. First, this was a retrospective study. Second, data were obtained from a single center. Larger, prospective, multicenter studies with inclusion of angiogenic biomarkers may improve our understanding of the pathophysiological basis of this challenging disease.

5. Conclusions

Mean platelet counts over the first 6 weeks of life do not significantly differ between infants with and without ROP after adjusting for confounders. The lower mean platelet counts observed in ROP infants are attributed to the effect of ROP-associated factors, particularly culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia. Clinicians should maintain a higher index of suspicion for ROP when screening premature infants with these risk factors.

Author Contributions

Conceptualization, Z.D.L., E.T.L.M., H.V.R. and I.S.; formal analysis, Z.D.L.; funding acquisition, E.T.L.M.; investigation, Z.D.L., E.P. and E.T.L.M.; methodology, Z.D.L., E.T.L.M., H.V.R. and I.S.; resources, E.T.L.M.; supervision, E.T.L.M., H.V.R. and I.S.; writing—original draft preparation, Z.D.L., E.P. and E.T.L.M.; writing—review and editing Z.D.L., E.P., E.T.L.M., H.V.R. and I.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a Universiti Sains Malaysia Research Grant (http://www.research.usm.my/, accessed on 6 February 2021), 304/PPSP/6315143, awarded to E.T.L.M. The funder had no role in study design; data collection and analysis; preparation of the manuscript; or decision to publish.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Human Research Ethics Committee of Universiti Sains Malaysia (USM/JEPeM/18090441, 17/12/2018).

Informed Consent Statement

Patient consent was waived as anonymised information was used.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We extend our thanks to all persons who contributed, directly or indirectly, to this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gilbert, C.; Fielder, A.; Gordillo, L.; Quinn, G.; Semiglia, R.; Visintin, P.; Zin, A. Characteristics of Infants With Severe Retinopathy of Prematurity in Countries With Low, Moderate, and High Levels of Development: Implications for Screening Programs. Pediatrics 2005, 115, e518–e525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Blencowe, H.; Lawn, J.E.; Vazquez, T.; Fielder, A.; Gilbert, C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr. Res. 2013, 74, 35–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. William, V. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans. Am. Ophthalmol. Soc. 2004, 102, 233–250. [Google Scholar]
  4. Al-Qahtani, B.; Al-Otaibi, M.; Alabdulajabbar, K.; Bin Selayem, N.; AlShehri, W.; Omair, A.; AlSaif, S. Retinopathy of Prematurity Incidence and Risk Factors in a Tertiary Hospital in Riyadh, Saudi Arabia. Middle East Afr. J. Ophthalmol. 2019, 26, 235–239. [Google Scholar] [CrossRef] [PubMed]
  5. AlBalawi, H.B.; AlBalawi, N.S.; AlSuhaimi, N.A.; AlBalawi, A.A.; Alatawi, A.S.; Mirghani, H.O.; Al-Dhibi, H.A.; Alenezi, S.H. Incidence and risk factors for retinopathy of prematurity in Tabuk city, KSA. Middle East Afr. J. Ophthalmol. 2020, 27, 105–109. [Google Scholar] [CrossRef] [PubMed]
  6. Braimah, I.Z.; Enweronu-Laryea, C.; Sackey, A.H.; Kenu, E.; Agyabeng, K.; Ofori-Adjei, I.-O.D.-B.; Beyuo, V.; Oku, A.; Essuman, V.A. Incidence and risk factors of retinopathy of prematurity in Korle-Bu Teaching Hospital: A baseline prospective study. BMJ Open 2020, 10, e035341. [Google Scholar] [CrossRef]
  7. Huang, H.-B.; Chen, Y.-H.; Wu, J.; Hicks, M.; Yi, Y.-Z.; Zhang, Q.-S.; Chow, C.-B.; Cheung, P.-Y. Early Risk Factors for Retinopathy of Prematurity in Very and Extremely Preterm Chinese Neonates. Front. Pediatr. 2020, 8, 553519. [Google Scholar] [CrossRef]
  8. Siswanto, J.; Ronoatmodjo, S.; Adisasmita, A.; Soemantri, A.; Sitorus, R.; Sauer, P. Risk factors for the development and progression of retinopathy of prematurity in preterm infants in Indonesia. J. Neonatal-Perinatal Med. 2020, 13, 253–260. [Google Scholar] [CrossRef]
  9. Coppinger, J.A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J.P.; Cahill, D.J.; Emili, A.; Fitzgerald, D.J.; Maguire, P.B. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103, 2096–2104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Battinelli, E.M. The Role of Platelets in Angiogenesis. Platelets 2019, 433–441. [Google Scholar] [CrossRef]
  11. Aksoy, H.T.; Eras, Z.; Canpolat, F.E.; Uras, N.; Oguz, S.S.; Dilmen, U. Corrected VEGF Levels Based on Platelet Count Should Be Calculated. Neonatology 2014, 105, 25. [Google Scholar] [CrossRef]
  12. Jensen, A.K.; Ying, G.-S.; Huang, J.; Quinn, G.E.; Binenbaum, G. Longitudinal study of the association between thrombocytopenia and retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2018, 22, 119–123. [Google Scholar] [CrossRef] [PubMed]
  13. Sancak, S.; Toptan, H.H.; Yildirim, T.G.; Karatekin, G.; Ovali, F. Thrombocytopenia as a Risk Factor for Retinopathy of Prematurity. Retina 2019, 39, 706–711. [Google Scholar] [CrossRef] [PubMed]
  14. Cakir, B.; Liegl, R.; Hellgren, G.; Lundgren, P.; Sun, Y.; Klevebro, S.; Löfqvist, C.; Mannheimer, C.; Cho, S.; Poblete, A.; et al. Thrombocytopenia is associated with severe retinopathy of prematurity. JCI Insight 2018, 3, 7–8. [Google Scholar] [CrossRef]
  15. Bourla, D.H.; Gonzales, C.R.; Valijan, S.; Yu, F.; Mango, C.W.; Schwartz, S.D. Association of Systemic Risk Factors with the Progression of Laser-Treated Retinopathy of Prematurity to Retinal Detachment. Retina 2008, 28, S58–S64. [Google Scholar] [CrossRef]
  16. Korkmaz, L.; Baştuğ, O.; Özdemir, A.; Korkut, S.; Karaca, Ç.; Akın, M.A.; Öztürk, M.A. Platelet mass index can be a reliable marker in predicting the prognosis of retinopathy of prematurity in very preterm infants. Pediatr. Neonatol. 2018, 59, 455–463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Del Rey Hurtado de Mendoza, B.; Esponera, C.B.; Renau, M.I.; Platas, I.I. Asymptomatic late thrombocytosis is a common finding in very preterm infants even in the absence of erythropoietin treatment. J. Int. Med. Res. 2019, 47, 1504–1511. [Google Scholar] [CrossRef] [Green Version]
  18. Gole, G.; Ells, A.L.; Katz, X.; Holmstrom, G.; Fielder, A.R.; Capone, A.; Flynn, J.T.; Good, W.G.; Holmes, J.M.; McNamara, J.; et al. The International Classification of Retinopathy of Prematurity Revisited. Arch. Ophthalmol. 2005, 123, 991–999. [Google Scholar] [CrossRef]
  19. Jensen, A.K.; Ying, G.-S.; Huang, J.; Karp, K.; Quinn, G.E.; Binenbaum, G. Thrombocytopenia and retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2011, 15, 447–450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Lundgren, P.; Lundberg, L.; Hellgren, G.; Holmström, G.; Hård, A.-L.; Smith, L.E.; Wallin, A.; Hallberg, B.; Hellström, A. Aggressive Posterior Retinopathy of Prematurity Is Associated with Multiple Infectious Episodes and Thrombocytopenia. Neonatology 2016, 111, 79–85. [Google Scholar] [CrossRef] [Green Version]
  21. Lundgren, P.; Nilsson, A.K.; Hellgren, G.; Pivodic, A.; Smith, L.E.; Hellström, A. Association between low fatty acid levels and platelet count in infants with Retinopathy of Prematurity. Acta Paediatr. 2020, 109, 2547–2548. [Google Scholar] [CrossRef] [PubMed]
  22. Rastogi, S.; Olmez, I.; Bhutada, A.; Rastogi, D. Drop in Platelet Counts in Extremely Preterm Neonates and Its Association with Clinical Outcomes. J. Pediatr. Hematol. 2011, 33, 580–584. [Google Scholar] [CrossRef] [PubMed]
  23. Sahinoglu-Keskek, N.; Akkoyun, I.; Çetinkaya, B. Platelet distribution width is a predictive marker for development of severe retinopathy of prematurity. Eye 2020, 1–2. [Google Scholar] [CrossRef]
  24. Hellström, A.; Smith, L.E.H.; Dammann, O. Retinopathy of prematurity. Lancet 2013, 382, 1445–1457. [Google Scholar] [CrossRef] [Green Version]
  25. Zhu, Z.; Hua, X.; Yu, Y.; Zhu, P.; Hong, K.; Ke, Y. Effect of red blood cell transfusion on the development of retinopathy of prematurity: A systematic review and meta-analysis. PLoS ONE 2020, 15, e0234266. [Google Scholar] [CrossRef] [PubMed]
  26. Hematyar, M.; Najibpour, R.; Bayesh, S.; Hojjat, A.; Farshad, A. Assessing the Role of Clinical Manifestations and Laboratory Findings in Neonatal Sepsis. Arch. Pediatr. Infect. Dis. 2016, 5. [Google Scholar] [CrossRef] [Green Version]
  27. Guclu, E.; Durmaz, Y.; Karabay, O. Effect of severe sepsis on platelet count and their indices. Afr. Health Sci. 2013, 13, 333–338. [Google Scholar] [CrossRef] [Green Version]
  28. Azevedo, L.C.P.; Janiszewski, M.; Soriano, F.G.; Laurindo, F.R.M. Redox Mechanisms of Vascular Cell Dysfunction in Sepsis. Endocr. Metab. Immune Disord. Drug Targets 2006, 6, 159–164. [Google Scholar] [CrossRef] [PubMed]
  29. Dewitte, A.; Lepreux, S.; Villeneuve, J.; Rigothier, C.; Combe, C.; Ouattara, A.; Ripoche, J. Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? Ann. Intensive Care 2017, 7, 1–18. [Google Scholar] [CrossRef] [Green Version]
  30. Ushio–Fukai, M. VEGF Signaling Through NADPH Oxidase-Derived ROS. Antioxid. Redox Signal. 2007, 9, 731–739. [Google Scholar] [CrossRef]
  31. Joussen, A.M.; Poulaki, V.; Le, M.L.; Koizumi, K.; Esser, C.; Janicki, H.; Schraermeyer, U.; Kociok, N.; Fauser, S.; Kirchhof, B.; et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18, 1450–1452. [Google Scholar] [CrossRef] [PubMed]
  32. Ibrahim, R.; Mohamed, D.; Abdelghaffar, S.; Mansi, Y. Red blood transfusion in preterm infants: Changes in glucose, electrolytes and acid base balance. Asian J. Transfus. Sci. 2012, 6, 36–41. [Google Scholar] [CrossRef]
  33. Silvain, J.; Abtan, J.; Kerneis, M.; Martin, R.; Finzi, J.; Vignalou, J.-B.; Barthélémy, O.; O’Connor, S.A.; Luyt, C.-E.; Bréchot, N.; et al. Impact of Red Blood Cell Transfusion on Platelet Aggregation and Inflammatory Response in Anemic Coronary and Noncoronary Patients. J. Am. Coll. Cardiol. 2014, 63, 1289–1296. [Google Scholar] [CrossRef] [Green Version]
  34. Banerjee, J.; Asamoah, F.; Morris, J.; Aladangady, N. PS-201 Association between Blood Transfusion and Development of Retinopathy of Prematurity—Systematic Review of Literature And Meta-analysis. Arch. Dis. Child. 2014, 99, A184–A185. [Google Scholar] [CrossRef] [Green Version]
  35. Stutchfield, C.J.; Jain, A.; Odd, D.; Williams, C.E.M.; Markham, R. Foetal haemoglobin, blood transfusion, and retinopathy of prematurity in very preterm infants: A pilot prospective cohort study. Eye 2017, 31, 1451–1455. [Google Scholar] [CrossRef]
  36. Ashton, N. Oxygen and the retinal blood vessels. Trans. Ophthalmol. Soc. 1980, 100, 359–362. [Google Scholar]
  37. Kirpalani, H.; Whyte, R.K.; Andersen, C.; Asztalos, E.V.; Heddle, N.; Blajchman, M.A.; Peliowski, A.; Rios, A.; Lacorte, M.; Connelly, R.; et al. The premature infants in need of transfusion (pint) study: A randomized, controlled trial of a restrictive (LOW) versus liberal (HIGH) transfusion threshold for extremely low birth weight infants. J. Pediatr. 2006, 149, 301–307.e3. [Google Scholar] [CrossRef] [PubMed]
  38. Chen, H.-L.; Tseng, H.-I.; Lu, C.-C.; Yang, S.-N.; Fan, H.-C.; Yang, R.-C. Effect of Blood Transfusions on the Outcome of Very Low Body Weight Preterm Infants under Two Different Transfusion Criteria. Pediatr. Neonatol. 2009, 50, 110–116. [Google Scholar] [CrossRef] [Green Version]
  39. Stark, A.; Dammann, C.; Nielsen, H.C.; Volpe, M.V. A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases. Front. Pediatr. 2018, 6, 125. [Google Scholar] [CrossRef]
  40. Singh, J.K.; Wymore, E.M.; Wagner, B.D.; Thevarajah, T.S.; Jung, J.L.; Kinsella, J.P.; Palestine, A.G.; Lynch, A.M. Relationship between severe bronchopulmonary dysplasia and severe retinopathy of prematurity in premature newborns. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2019, 23, 209.e1–209.e4. [Google Scholar] [CrossRef] [PubMed]
  41. Kjellberg, M.; Sanchez-Crespo, A.; Jonsson, B. Ten-year-old children with a history of bronchopulmonary dysplasia have regional abnormalities in ventilation perfusion matching. Pediatr. Pulmonol. 2019, 54, 602–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Langdon, J.R.; McDonald, T.P. Effects of chronic hypoxia on platelet production in mice. Exp. Hematol. 1977, 5, 191–198. [Google Scholar] [PubMed]
  43. McDonald, T.P.; Cottrell, M.; Clift, R. Effects of short-term hypoxia on platelet counts of mice. Blood 1978, 51, 165–175. [Google Scholar] [CrossRef] [Green Version]
  44. Boström, H.; Willetts, K.; Pekny, M.; Levéen, P.; Lindahl, P.; Hedstrand, H.; Pekna, M.; Hellström, M.; Gebre-Medhin, S.; Schalling, M.; et al. PDGF-A Signaling Is a Critical Event in Lung Alveolar Myofibroblast Development and Alveogenesis. Cell 1996, 85, 863–873. [Google Scholar] [CrossRef] [Green Version]
  45. Wiedmeier, S.E.; Henry, E.; Sola-Visner, M.C.; Christensen, R.D. Platelet reference ranges for neonates, defined using data from over 47 000 patients in a multihospital healthcare system. J. Perinatol. 2009, 29, 130–136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. The United Nations Children’s Fund. UNICEF Data Warehouse. Available online: https://data.unicef.org/resources/data_explorer/unicef_f/?ag=UNICEF&df=GLOBAL_DATAFLOW&ver=1.0&dq=.CME_MRM0.&startPeriod=2016&endPeriod=2019 (accessed on 8 December 2020).
  47. World Health Organization. Neonatal Mortality Rate (per 1000 Live Births). Available online: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/neonatal-mortality-rate-(per-1000-live-births) (accessed on 8 December 2020).
Figure 1. Mean platelet count in groups with and without retinopathy of prematurity (ROP) from birth to week 6 of life pre-and postadjustment for confounders (culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia). This graphical depiction of the weekly mean platelet count in infants with and without ROP demonstrates that the difference between the two groups disappears after adjusting for covariates.
Figure 1. Mean platelet count in groups with and without retinopathy of prematurity (ROP) from birth to week 6 of life pre-and postadjustment for confounders (culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia). This graphical depiction of the weekly mean platelet count in infants with and without ROP demonstrates that the difference between the two groups disappears after adjusting for covariates.
Ijerph 18 03783 g001
Table 1. Clinical characteristics of infants with and without retinopathy of prematurity (ROP).
Table 1. Clinical characteristics of infants with and without retinopathy of prematurity (ROP).
Clinical FeaturesROP
n = 31
No ROP
n = 62
p Value
Mean birth weight (g)962.2 ± 167.91056.9 ± 173.80.014 *,a
Mean gestational age (weeks)27.6 ± 1.928.5 ± 1.40.013 *,a
Respiratory distress syndrome29 (93.5%)59 (95.1%)0.745 b
Surfactant usage27 (87.1%)57 (91.9%)0.457 b
Intraventricular hemorrhage17 (54.8%)29 (46.7%)0.463 b
Culture-proven sepsis16 (51.6%)4 (6.4%)<0.001 *,b
Pneumonia10 (32.2%)13 (20.9%)0.234 b
Necrotizing enterocolitis5 (16.1%)13 (20.9%)0.578 b
Congenital heart disease10 (32.2%)11 (17.7%)0.114 b
Blood transfusion (mL)104.3 ± 62.348.7 ± 28.3<0.001 *,a
Bronchopulmonary dysplasia12 (38.7%)4 (6.4%)<0.001 *,b
Supplemental oxygenation (days)14.4 ± 17.12.7 ± 3.7<0.001 *,a
Multiple gestation11 (35.4%)13 (20.9%)0.132 b
Gender (male)16 (51.6%)40 (64.5%)0.587 b
a Independent t-test was applied. b Pearson chi-square test was applied. * p < 0.05 indicates statistical significance.
Table 2. Factors associated with ROP.
Table 2. Factors associated with ROP.
VariablesSimple Logistic RegressionMultiple Logistic Regression
βp ValueOR (95% CI)βp ValueOR (95% CI)
Mean birth weight (g)−0.0510.017 *0.950 (0.911–0.991)
Mean gestational age (days)−0.0030.017 *0.997 (0.994–0.999)
Blood transfusion (mL)0.037<0.001 *1.038 (1.020–1.056)0.0310.003 *1.030 (1.010–1.056)
Supplemental oxygenation (days)0.1540.003 *1.167 (1.054–1.292)
Intraventricular haemorrhage0.3230.4641.382 (0.581–3.284)
Culture-proven sepsis2.739<0.001 *15.467 (4.503–53.128)2.1740.003 *8.792 (2.093–36.936)
Pneumonia0.5850.5851.795 (0.680–4.735)
Necrotizing enterocolitis−0.3220.5790.725 (0.233–2.257)
Congenital heart disease0.7920.1192.208 (0.816–5.976)
Bronchopulmonary dysplasia2.519<0.001 *12.421 (3.167–48.721)1.8590.023 *6.416 (1.289–31.933)
* p < 0.05 indicates statistical significance.
Table 3. Comparison of mean platelet counts between infants with and without ROP based on time.
Table 3. Comparison of mean platelet counts between infants with and without ROP based on time.
Mean Platelet Counts (000/ μL)Adjusted Mean (95% CI)p Value ap Value b
ROPNo ROP
Without Covariates
Birth226.25 (205.34,247.17)216.85 (202.06, 231.64)0.4680.002 *
Week 1179.75 (160.77,198.74)190.85 (177.42, 204.27)0.346
Week 2218.34 (178.44,258.24)300.72 (272.50, 328.93)0.001 *
Week 3300.04 (249.08,351.01)384.48 (348.44, 420.52)0.009 *
Week 4314.93 (261.78, 368.09)399.23 (361.64, 436.81)0.012 *
Week 5313.82 (259.34, 368.30)412.08 (373.56, 450.60)0.004 *
Week 6 321.71 (271.60, 371.82)409.65 (374.22, 445.09)0.005 *
With covariates ap Value cp Value d
Birth238.00 (213.45, 262.54)210.98 (195.04, 226.92)0.1070.489
Week 1198.66 (176.93, 220.40)181.39 (167.28, 195.51)0.258
Week 2261.75 (216.48, 307.03)279.01 (249.61, 308.41)0.484
Week 3378.99 (325.57, 432.41)345.01 (310.32, 379.70)0.400
Week 4366.71 (307.06, 426.36)373.34 (334.60, 412.08)0.838
Week 5372.88 (310.78, 434.98)382.55 (342.23, 422.88)0.777
Week 6364.71 (310.50, 418.92)388.15 (352.95, 423.35)0.562
a Repeated measure ANOVA between groups. b Repeated measure ANOVA within–between groups (overall). c Repeated measure ANCOVA between groups, adjusted for culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia. d Repeated measure ANCOVA within–between groups (overall), adjusted for culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia.* p < 0.05 indicates statistical significance.
Table 4. Comparison of mean platelet counts between different stages of ROP.
Table 4. Comparison of mean platelet counts between different stages of ROP.
TimeMean Platelet Counts ± SD (000/μL)
No ROP
N = 62
ROP Stage 1
N = 8
ROP Stage 2
N = 6
ROP Stage 3 or More
N = 17
p Value ap Value bp Value c
Birth 216.8 ± 57.5219.1 ± 71.1282.5 ± 36.8209.7 ± 52.80.0740.0710.926
Week 1190.8 ± 48.4190.4 ± 61.0 213.9 ± 70.0162.6 ± 56.30.1800.561
Week 2300.7 ± 115.1245.0 ± 134.7274.3 ± 66.4186.0 ± 92.90.004 *0.852
Week 3384.4 ± 137.1364.8 ± 181.4370.2 ± 136.3244.7 ± 130.30.006 *0.846
Week 4399.2 ± 135.0379.0 ± 194.5334.9 ± 111.4277.7 ± 180.40.041 *0.887
Week 5412.0 ± 155.7438.4 ± 178.3317.3 ± 97.3253.9 ± 107.90.002 *0.258
Week 6409.6 ± 142.0367.1 ± 85.0382.7 ± 125.1278.7 ± 151.10.023 *0.923
a Repeated measure ANOVA between groups. b Repeated measure ANCOVA between groups, adjusted for culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia. c Repeated measure ANCOVA within–between groups (overall), adjusted for culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia. * p < 0.05 indicates statistical significance.
Table 5. Summary of literature regarding platelet counts in ROP.
Table 5. Summary of literature regarding platelet counts in ROP.
NameCountryYearSample SizeStudyResultConclusions
Bourla et al. [15]USA2008178Retrospective p = 0.689No association between thrombocytopenia and ROP
Rastogi et al. [22]USA2011286Retrospectivep < 0.001A >30% drop in platelet counts is associated with ROP
Jensen et al. [19]USA2011161RetrospectiveOR 6.69, 95% CI 2.82–15.9Thrombocytopenia is associated with severe ROP, primarily in zone 1
Lundgren et al. [20]USA201718Retrospectivep < 0.001Thrombocytopenia at the time of ROP diagnosis is associated with APROP development
Korkmaz et al. [16]Turkey2017146Retrospectivep > 0.05Platelet counts do not differ between groups with and without ROP
Cakir et al. [14]USA2018202RetrospectiveOR 2.97 95% CI (1.37–6.46)Thrombocytopenia is independently associated with severe ROP
Sancak et al. [13]Turkey2018182RetrospectiveOR 59.0, 95% CI 51.14–71.0There is a significant association between thrombocytopenia and Type I ROP
Jensen et al. [12]USA2018100Retrospective OR 2.8, 95% CI 1.4–5.6Thrombocytopenia from birth to 34 weeks GA is associated with subsequent severe ROP
Lundgren et al. [21]Sweden202078Prospectivep < 0.01ROP requiring treatment had lower platelet counts than ROP not requiring treatment
ROP, retinopathy of prematurity; APROP, aggressive posterior retinopathy of prematurity; GA, Gestational age.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lim, Z.D.; Pheng, E.; Min, E.T.L.; Van Rostenberghe, H.; Shatriah, I. Comparison of Mean Platelet Counts in Preterm Infants with and without Retinopathy of Prematurity. Int. J. Environ. Res. Public Health 2021, 18, 3783. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073783

AMA Style

Lim ZD, Pheng E, Min ETL, Van Rostenberghe H, Shatriah I. Comparison of Mean Platelet Counts in Preterm Infants with and without Retinopathy of Prematurity. International Journal of Environmental Research and Public Health. 2021; 18(7):3783. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073783

Chicago/Turabian Style

Lim, Zi Di, Edwin Pheng, Evelyn Tai Li Min, Hans Van Rostenberghe, and Ismail Shatriah. 2021. "Comparison of Mean Platelet Counts in Preterm Infants with and without Retinopathy of Prematurity" International Journal of Environmental Research and Public Health 18, no. 7: 3783. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073783

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop